382185 HDAC Inhibitor XXII, NCH51 - CAS 848354-66-5 - Calbiochem

382185
View Pricing & Availability

Overview

Replacement Information

Key Specifications Table

Empirical FormulaCAS #
C₂₀H₂₆N₂O₂S₂ 848354-66-5

Pricing & Availability

Catalog Number AvailabilityPackaging Qty/Pack Price Quantity
382185-2MG
Retrieving availability...
Limited AvailabilityLimited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

      Glass bottle 2 mg
      Retrieving price...
      Price could not be retrieved
      Minimum Quantity needs to be mulitiple of
      Upon Order Completion More Information
      You Saved ()
       
      Request Pricing
      Description
      OverviewA cell-permeable S-isobutyryl prodrug that is processed intracellularly to form the potent HDAC inhibitor NCH-31 (IC50 = 48 and 170 nM, respectively, using partially purified HDAC1 or HeLa nuclear extract) that is predicted to exhibit a similar HADC binding mode as that of SAHA with its sulfhydryl replacing SAHA's hydroxamate as the active-site zinc-targeting group. NCH-51 is shown to exhibit comparable antiproliferative (mean IC50 = 3.8 µM vs. 3.7 µM for SAHA; 48 h treatment) and apoptotic activity as SAHA against various cancer cell lines, but not PBMCs from 4 healthy individuals (IC50 >30 µM with either drug), and the antioxidant N-Acetyl-L-Cysteine (NAC; Cat. No. 106425) at 2 mM is reported to abolish the cell-growth inhibition caused by either 3 µM NCH-51 or SAHA in the Multiple Myeloma U266 cultures. Half-life in human plasma at 37 °C = 24 h.
      Catalogue Number382185
      Brand Family Calbiochem®
      SynonymsThioisobutyric acid (S-(6-(4-phenyl-2-thiazolylcarbamoyl)hexyl) ester
      References
      ReferencesSanda, T., et al. 2007. Leukemia 21, 2344.
      Suzuki, T., et al. 2007. Bioorg. Med. Chem. Lett. 17, 1558.
      Suzuki, T., et al. 2005. J. Med. Chem. 48, 1019.
      Product Information
      CAS number848354-66-5
      FormWhite powder
      Hill FormulaC₂₀H₂₆N₂O₂S₂
      Chemical formulaC₂₀H₂₆N₂O₂S₂
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Application Comments#31: Thiol - 7-Mercaptoheptanoic acid (4-phenyl-2-thiazolyl)amide
      Biological Information
      Purity≥97% by HPLC
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Shipped with Blue Ice or with Dry Ice
      Toxicity Regulatory Review
      Storage -20°C
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications

      Documentation

      HDAC Inhibitor XXII, NCH51 - CAS 848354-66-5 - Calbiochem SDS

      Title

      Safety Data Sheet (SDS) 

      HDAC Inhibitor XXII, NCH51 - CAS 848354-66-5 - Calbiochem Certificates of Analysis

      TitleLot Number
      382185

      References

      Reference overview
      Sanda, T., et al. 2007. Leukemia 21, 2344.
      Suzuki, T., et al. 2007. Bioorg. Med. Chem. Lett. 17, 1558.
      Suzuki, T., et al. 2005. J. Med. Chem. 48, 1019.
      Data Sheet

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision14-November-2011 RFH
      SynonymsThioisobutyric acid (S-(6-(4-phenyl-2-thiazolylcarbamoyl)hexyl) ester
      DescriptionA cell-permeable S-isobutyryl prodrug that is processed intracellularly to form the potent HDAC inhibitor NCH-31 (IC50 = 48 and 170 nM, respectively, using partially purified HDAC1 or HeLa nuclear extract) that is predicted to exhibit a similar HADC binding mode as that of SAHA with its sulfhydryl replacing SAHA's hydroxamate as the active-site zinc-targeting group. NCH-51 is shown to exhibit comparable antiproliferative (mean IC50 = 3.8 µM vs. 3.7 µM for SAHA; 48 h treatment) and apoptotic activity as SAHA against various cancer cell lines, but not PBMCs from 4 healthy individuals (IC50 >30 µM with either drug), and the antioxidant N-Acetyl-L-Cysteine (NAC; Cat. No. 106425) at 2 mM is reported to abolish the cell-growth inhibition caused by either 3 µM NCH-51 or SAHA in the Multiple Myeloma U266 cultures. Half-life in human plasma at 37 °C = 24 h.
      FormWhite powder
      CAS number848354-66-5
      Chemical formulaC₂₀H₂₆N₂O₂S₂
      Structure formulaStructure formula
      Purity≥97% by HPLC
      SolubilityDMSO (100 mg/ml)
      Comments#31: Thiol - 7-Mercaptoheptanoic acid (4-phenyl-2-thiazolyl)amide
      Storage -20°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Toxicity Regulatory Review
      ReferencesSanda, T., et al. 2007. Leukemia 21, 2344.
      Suzuki, T., et al. 2007. Bioorg. Med. Chem. Lett. 17, 1558.
      Suzuki, T., et al. 2005. J. Med. Chem. 48, 1019.